0.2599

13.00% +0.0299

After Hours: .2889 0.029 +11.16%

Portage Biotech Inc (PRTG)

Overview News Price History Option Chain Why PRTG Down? Discussions Forecast Stock Split

Portage Biotech Inc stock is currently priced at $0.2599, with a 24-hour trading volume of 38,452. It has seen a +13.00% increased in the last 24 hours and a -50.71% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.2403 pivot point. If it approaches the $0.2712 resistance level, significant changes may occur.

Previous Close:

$0.23

Open:

$0.231

24h Volume:

38,452

Market Cap:

$5.14M

Revenue:

Net Income/Loss:

$-144.90M

P/E Ratio:

-0.039

EPS:

-6.67

Net Cash Flow:

$-12.08M

1W Performance:

+9.66%

1M Performance:

-50.71%

6M Performance:

-86.67%

1Y Performance:

-92.90%

1D Range:

$0.231

$0.26

52W Range:

$0.1999

$4.40

Portage Biotech Inc Stock (PRTG) Company Profile

Name

Portage Biotech Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

Address

Craigmuir Chambers, Road Town, Tortola

Employee

Twitter

Next Earnings Date

2024-05-14

Latest SEC Filings

PRTG's Discussions on Twitter

Portage Biotech Inc Stock (PRTG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-07-22	Initiated	H.C. Wainwright	Buy
Sep-21-21	Initiated	Oppenheimer	Outperform
Sep-02-21	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Cantor Fitzgerald	Overweight

Portage Biotech Inc Stock (PRTG) Latest News

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

GlobeNewswire Inc.

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

GlobeNewswire Inc.

Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Why Fusion Pharmaceuticals Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket

Benzinga

Portage Biotech Inc Stock (PRTG) Financials Data

Portage Biotech Inc (PRTG) Net Income 2024

PRTG net income (TTM) was -$144.90 million for the quarter ending December 31, 2023, a -728.94% decrease year-over-year.

Portage Biotech Inc (PRTG) Cash Flow 2024

PRTG recorded a free cash flow (TTM) of -$12.08 million for the quarter ending March 31, 2023, a -78.53% decrease year-over-year.

Portage Biotech Inc (PRTG) Earnings per Share 2024

PRTG earnings per share (TTM) was -$8.34 for the quarter ending December 31, 2023, a -606.78% decline year-over-year.

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors. It also provides Nanolipogel (NLG) co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.